Overall sales in the pharmaceutical contract manufacturing and contract research market were worth nearly $143 million in 2007, which increased to an estimated $177 million in 2009. By 2014, sales are projected to increase to nearly $299 million, for a 5-year CAGR of 11.1%.
The largest segment in the market, contract manufacture of OTC and nutraceuticals, was valued at $82 million in 2007. This increased to an estimated $103 million in 2009, and is projected to reach $177 million in 2014, for a 5-year CAGR of 11.4%.
Sales in the contract manufacture of bulk- and dosage-form drugs segment were worth $36 million in 2007, and were to increase to nearly $44 million in 2009. By 2014, they are projected to increase to $73 million, for a 5-year CAGR of 10.8%.
(0 items)
